DelveInsight Business Research LLP
Albany, NY -- (SBWIRE) -- 06/21/2019 -- Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2028
1. Pancreatic cancer is the fourth-leading cause of cancer death in both men and women, with an estimated 43,090 deaths in 2017.
2. Pancreatic cancer has been diagnosed in the US in 2017 with 53,670 new cases.
3. Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths.
(Albany, US) DelveInsight launched a new report on Pancreatic cancer Market Insights, Epidemiology and Market Forecast-2028
1. Pancreatic cancer market report covers a descriptive overview and comprehensive insight of the Pancreatic cancer epidemiology and Pancreatic cancer market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Pancreatic cancer market report provides insights on the current and emerging therapies.
3. Pancreatic cancer market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Pancreatic cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pancreatic cancer market.
Request for sample pages
"From 2004 to 2013, the incident rate of pancreatic cancer has been increased by about 1% per year."
Pancreatic cancer treatment options depend upon the type and stage of cancer along with its location, whether it is in the pancreas or has spread to any of the surrounding organs and blood vessels. Pancreatic cancer is quite difficult to treat in its early stages as this type of cancer rarely causes symptoms, so it's often not detected until it's quite advanced. If the tumour is large or has spread, treating or curing the cancer is much harder.
The availability of expensive Pancreatic cancer treatment and poor reimbursement policies in the developing regions of the world are some of the factors which may hamper the Pancreatic cancer market growth during the forecast period, however the overall pancreatic cancer market is expected to experience a positive growth owing to the launch of distinctive emerging Pancreatic cancer therapies, continuous investment of huge amount of funds to improve patient-centered care by the government, advancing technology in medical devices, increase in geriatric population base, increase in Pancreatic cancer prevalence along with the increase in number of diagnosis of this disease during the forecast period (2019-2028).
Pancreatic cancer market size shall increase during the forecast period (2019- 2028) due to the launch of Pancreatic cancer upcoming therapies like:-
And many others
The major players in Pancreatic cancer market are:-
1. ARMO BioSciences
2. Rafael Pharmaceuticals
3. Merrimack Pharmaceuticals
4. Hutchison Medipharma
And many others
Table of contents
1. Report Introduction
2. Pancreatic cancer Market Overview at a Glance
3. Pancreatic cancer Disease Background and Overview
4. Pancreatic cancer Epidemiology and Patient Population
5. Pancreatic cancer Country- Wise Epidemiology
5.1. United States
5.2.1.Assumptions and Rationale
6. Pancreatic cancer Treatments & Medical Practices
7. Pancreatic cancer Marketed Products
7.1. Tarceva (erlotinib): Hoffmann-La Roche
7.2. ONIVYDE (irinotecan liposome injection): Merrimack Pharmaceuticals
8. Pancreatic cancer Current Unmet Need
9. Pancreatic cancer Emerging Therapies
9.1. Key Cross Competition
9.2. AM0010 : ARMO BioSciences
9.3. BPM31510: Berg LLC
10. Pancreatic cancer Market Size
11. 7MM Pancreatic cancer Country-Wise Market Analysis
11.1.United States Market Size
11.2.Germany Market Size
11.3.France Market Size
11.4.United Kingdom Market Size
11.5.Spain Market Size
11.6.Italy Market Size
11.7. Japan Market Size
12. Market Driver
13. Market Barriers
14. Pancreatic cancer Report Methodology
15. DelveInsight Capabilities
17. About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.